NCT04250493 Insulin Resistance in Multiple System Atrophy
| NCT ID | NCT04250493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Multiple System Atrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 124 participants |
| Start Date | 2020-10-28 |
| Primary Completion | 2026-10-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 124 participants in total. It began in 2020-10-28 with a primary completion date of 2026-10-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.
Eligibility Criteria
Inclusion Criteria: Patients : * Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al., 2008). * Age \> 30 * Written informed consent * Patient covered by the national health system Controls: * Patients not suffering from a neurologic disorder * Age \> 30 * Written informed consent * Patient covered by the national health system Exclusion Criteria: For patients and controls: * Presence of a diabetes * Treatment with corticosteroids, estrogen, atypical antipsychotics, and anti-retroviral agents * Patient under tutelage * Patient unable to give consent * Any other neurologic disorder * Pregnancy and breastfeeding * MOCA ≤21 * Contraindication to perform an MRI
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04250493 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Multiple System Atrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04250493 currently recruiting?
Yes, NCT04250493 is actively recruiting participants. Contact the research team at wassilios.meissner@chu-bordeaux.fr for enrollment information.
Where is the NCT04250493 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT04250493 clinical trial?
NCT04250493 is sponsored by University Hospital, Bordeaux. The trial plans to enroll 124 participants.